Entera Bio Ltd
ILILSEntera Bio Ltd (US:ENTX) — Biotechnology: Biological Products (No Diagnostic Substances). Number of exchanges where the company shares trade: 1. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- enterabio.com
- Investor relations
- investors.enterabio.com/
- Sector
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Headquarters
- JERUSALEM, Israel
- Management
- Miranda J. Toledano
- Latest reports
- Employees
- 20
- Shares outstanding
- 173.14 M as of 2026-08-03
- Free float
- 126.58 M
- Market cap
- 507.6 M USD
- Insiders
- 5.43%
- Institutions
- 34.09%
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- loss
- P/B
- 21.2
- FCF
- −11.0 M USD
- Debt
- 3.89 M USDnegative FCF — not covered
- Earnings and FCF — for the 12 months to 30.06.2026 (the company's latest report).
- Net income
- NAV
Description
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Exchanges and tickers
| Exchange | Ticker | Currency | Price | Type |
|---|---|---|---|---|
| US USA Stocks | ENTX | USD | 3.12 +0.65% | common stock |
News this week
Press releases from the company's investor website, updated daily. Links lead to the company's website. Headlines are in the original language, as on the company website.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Knoll Capital Management… | 3.38% | 5.88 M | 2026-06-30 |
| BVF Inc. | 1.39% | 2.43 M | 2026-06-30 |
| TOLEDANO MIRANDA JAYNE (… | ≈0.49% | 847 135 | 2026-07-14 |
| Siren, L.L.C. | 0.42% | 736 457 | 2026-06-30 |
| Renaissance Technologies… | 0.21% | 368 847 | 2026-06-30 |
| LIEBERMAN GERALD M (Dire… | ≈0.21% | 363 254 | 2025-12-31 |
| Parkman Healthcare Partn… | 0.16% | 274 497 | 2026-06-30 |
| PNC Financial Services G… | 0.16% | 273 031 | 2026-06-30 |
| ELLIS SEAN (Director) | ≈0.12% | 208 132 | 2026-08-07 |
| Seven Fleet Capital Mana… | 0.11% | 191 354 | 2026-06-30 |
| BURSHTEIN GREGORY (Offic… | ≈0.11% | 189 033 | 2026-05-07 |
| Fidelity Concord Street… | 0.1% | 178 259 | 2026-08-31 |
| GALITZER HILLEL M.D. (Ch… | ≈0.09% | 163 566 | 2026-05-07 |
| TAITEL HAYA (Director) | ≈0.07% | 119 269 | 2026-08-07 |
| MALCA YONATAN (Director) | ≈0.06% | 100 231 | 2026-08-07 |
| OSTROV GERALD M (Directo… | ≈0.04% | 75 657 | 2025-12-31 |
| HighTower Advisors, LLC | 0.04% | 74 573 | 2026-06-30 |
| HRT Financial LP | 0.04% | 72 486 | 2026-06-30 |
| Schonfeld Strategic Advi… | 0.03% | 58 871 | 2026-06-30 |
| GERMANO GENO J (Director… | ≈0.02% | 40 000 | 2026-03-09 |
| YAACOV-GARBELI DANA CPA… | — | — | 2026-05-07 |
Sign in with Google